Actively Recruiting
Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-10-09
900
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.
CONDITIONS
Official Title
Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma based on standard diagnostic guidelines
- Voluntary signing of informed consent
You will not qualify if you...
- Not suitable to participate as judged by the investigator
- Hepatic malignant tumors invading main portal vein, common hepatic duct, main hepatic vein, inferior vena cava, or having extrahepatic metastases
- Surgery involving biliary tract exploration or reconstruction due to biliary obstruction
- Surgery combined with splenectomy or splenic artery ligation
- Preoperative major underlying diseases of heart, lung, kidney, or other organs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
K
Kai Wang, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here